Meiji Yasuda America Inc purchased a new position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 11,514 shares of the company’s stock, valued at approximately $1,449,000.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Hikari Tsushin Inc. grew its stake in Zoetis by 295.8% during the 4th quarter. Hikari Tsushin Inc. now owns 164,238 shares of the company’s stock worth $20,664,000 after buying an additional 122,744 shares during the last quarter. UniSuper Management Pty Ltd grew its stake in Zoetis by 205.3% during the 4th quarter. UniSuper Management Pty Ltd now owns 135,910 shares of the company’s stock worth $17,100,000 after buying an additional 91,390 shares during the last quarter. IFM Investors Pty Ltd grew its stake in Zoetis by 0.7% during the 4th quarter. IFM Investors Pty Ltd now owns 86,914 shares of the company’s stock worth $10,936,000 after buying an additional 630 shares during the last quarter. TCTC Holdings LLC grew its stake in Zoetis by 1.3% during the 4th quarter. TCTC Holdings LLC now owns 40,519 shares of the company’s stock worth $5,098,000 after buying an additional 503 shares during the last quarter. Finally, Vaughan David Investments LLC IL grew its stake in Zoetis by 3.6% during the 4th quarter. Vaughan David Investments LLC IL now owns 217,318 shares of the company’s stock worth $27,343,000 after buying an additional 7,472 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.
Zoetis Trading Up 0.3%
Shares of ZTS stock opened at $81.51 on Friday. The business’s 50 day moving average is $97.70 and its two-hundred day moving average is $114.47. Zoetis Inc. has a twelve month low of $72.38 and a twelve month high of $168.83. The company has a market capitalization of $34.17 billion, a P/E ratio of 13.52, a price-to-earnings-growth ratio of 1.27 and a beta of 0.75. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.
Zoetis Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is 35.16%.
Zoetis News Roundup
Here are the key news stories impacting Zoetis this week:
- Negative Sentiment: Multiple law firms, including Rosen, Bronstein Gewirtz & Grossman, the Schall Law Firm, DJS Law Group, and others, urged investors to join or lead a class action against Zoetis, keeping litigation risk in focus and potentially weighing on sentiment. Article Title
- Negative Sentiment: The lawsuits allege Zoetis misled investors about weakening veterinarian adoption and prescription trends, which could raise concerns about the company’s underlying growth outlook and create overhang on the stock. Article Title
- Neutral Sentiment: Rosen Law Firm and others reminded shareholders that July 27, 2026 is the lead-plaintiff deadline, but these notices are procedural and do not change Zoetis’ fundamentals by themselves. Article Title
- Neutral Sentiment: Bank of America Securities reportedly maintained a “Hold” rating on Zoetis, which suggests Wall Street remains cautious but not overtly bearish. Article Title
Analysts Set New Price Targets
A number of research analysts recently issued reports on the company. Bank of America raised their price target on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Morgan Stanley restated an “overweight” rating and set a $115.00 price target on shares of Zoetis in a research note on Friday, May 15th. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Finally, Argus restated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Six equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $133.92.
Get Our Latest Research Report on ZTS
Insider Buying and Selling at Zoetis
In related news, Director Frank A. Damelio bought 6,650 shares of the stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the purchase, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Paul Bisaro bought 2,000 shares of the stock in a transaction on Wednesday, May 13th. The stock was bought at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have purchased 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by insiders.
About Zoetis
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Featured Articles
- Five stocks we like better than Zoetis
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
